Drug Profile
Empagliflozin/linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company
Alternative Names: Empagliflozin/linagliptin/metformin extended release; Empagliflozin/metformin/linagliptin; EmpaLinaMet XR; Linagliptin/empagliflozin/metformin; Linagliptin/metformin/empagliflozin; Metformin/empagliflozin/linagliptin; Metformin/linagliptin/empagliflozin; Trijardy™ XRLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Type 2 diabetes mellitus